The Irony of Iron: The Element with Diverse Influence on Neurodegenerative Diseases

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Apr 27

PMID 38673855

Authors

Seojin Lee

Gabor G Kovacs

Affiliations

Soon will be listed here.

Abstract

Iron accumulation in the brain is a common feature of many neurodegenerative diseases. Its involvement spans across the main proteinopathies involving tau, amyloid-beta, alpha-synuclein, and TDP-43. Accumulating evidence supports the contribution of iron in disease pathologies, but the delineation of its pathogenic role is yet challenged by the complex involvement of iron in multiple neurotoxicity mechanisms and evidence supporting a reciprocal influence between accumulation of iron and protein pathology. Here, we review the major proteinopathy-specific observations supporting four distinct hypotheses: (1) iron deposition is a consequence of protein pathology; (2) iron promotes protein pathology; (3) iron protects from or hinders protein pathology; and (4) deposition of iron and protein pathology contribute parallelly to pathogenesis. Iron is an essential element for physiological brain function, requiring a fine balance of its levels. Understanding of disease-related iron accumulation at a more intricate and systemic level is critical for advancements in iron chelation therapies.

Citing Articles

The Underestimated Role of Iron in Frontotemporal Dementia: A Narrative Review.

Ferretti S, Zanella I Int J Mol Sci. 2024; 25(23).

PMID: 39684697 PMC: 11640923. DOI: 10.3390/ijms252312987.

Postencephalitic Parkinsonism: Unique Pathological and Clinical Features-Preliminary Data.

Strobel S, Sian-Hulsmann J, Tappe D, Jellinger K, Riederer P, Monoranu C Cells. 2024; 13(18.

PMID: 39329695 PMC: 11430219. DOI: 10.3390/cells13181511.

Advancing cerebral small vessel disease diagnosis: Integrating quantitative susceptibility mapping with MRI-based radiomics.

Cheng Z, Yang L, Liang C, Li M, Li X, Chen Y Hum Brain Mapp. 2024; 45(13):e70022.

PMID: 39254181 PMC: 11386328. DOI: 10.1002/hbm.70022.

The Cellular Stability Hypothesis: Evidence of Ferroptosis and Accelerated Aging-Associated Diseases as Newly Identified Nutritional Pentadecanoic Acid (C15:0) Deficiency Syndrome.

Venn-Watson S Metabolites. 2024; 14(7).

PMID: 39057678 PMC: 11279173. DOI: 10.3390/metabo14070355.

Beyond Macrostructure: Is There a Role for Radiomics Analysis in Neuroimaging ?.

Das S, Ilesanmi A, Wolk D, Gee J Magn Reson Med Sci. 2024; 23(3):367-376.

PMID: 38880615 PMC: 11234947. DOI: 10.2463/mrms.rev.2024-0053.

References

Wong B, Tsatsanis A, Lim L, Adlard P, Bush A, Duce J . β-Amyloid precursor protein does not possess ferroxidase activity but does stabilize the cell surface ferrous iron exporter ferroportin. PLoS One. 2014; 9(12):e114174. PMC: 4252103. DOI: 10.1371/journal.pone.0114174. View

Uchida Y, Kan H, Sakurai K, Arai N, Kato D, Kawashima S . Voxel-based quantitative susceptibility mapping in Parkinson's disease with mild cognitive impairment. Mov Disord. 2019; 34(8):1164-1173. DOI: 10.1002/mds.27717. View

Ortega R, Carmona A, Roudeau S, Perrin L, Ducic T, Carboni E . α-Synuclein Over-Expression Induces Increased Iron Accumulation and Redistribution in Iron-Exposed Neurons. Mol Neurobiol. 2015; 53(3):1925-1934. DOI: 10.1007/s12035-015-9146-x. View

Hoglinger G, Respondek G, Stamelou M, Kurz C, Josephs K, Lang A . Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord. 2017; 32(6):853-864. PMC: 5516529. DOI: 10.1002/mds.26987. View

Baringer S, Lukacher A, Palsa K, Kim H, Lippmann E, Spiegelman V . Amyloid-β exposed astrocytes induce iron transport from endothelial cells at the blood-brain barrier by altering the ratio of apo- and holo-transferrin. J Neurochem. 2023; 167(2):248-261. PMC: 10592116. DOI: 10.1111/jnc.15954. View

Friedlich A, Tanzi R, Rogers J . The 5'-untranslated region of Parkinson's disease alpha-synuclein messengerRNA contains a predicted iron responsive element. Mol Psychiatry. 2007; 12(3):222-3. DOI: 10.1038/sj.mp.4001937. View

Slomka A, Switonska M, Zekanowska E . Hepcidin Levels Are Increased in Patients with Acute Ischemic Stroke: Preliminary Report. J Stroke Cerebrovasc Dis. 2015; 24(7):1570-6. DOI: 10.1016/j.jstrokecerebrovasdis.2015.03.031. View

Alushaj E, Hemachandra D, Kuurstra A, Menon R, Ganjavi H, Sharma M . Subregional analysis of striatum iron in Parkinson's disease and rapid eye movement sleep behaviour disorder. Neuroimage Clin. 2023; 40:103519. PMC: 10568416. DOI: 10.1016/j.nicl.2023.103519. View

Rogers J, Randall J, Cahill C, Eder P, Huang X, Gunshin H . An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem. 2002; 277(47):45518-28. DOI: 10.1074/jbc.M207435200. View

10.

Lei P, Ayton S, Finkelstein D, Spoerri L, Ciccotosto G, Wright D . Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med. 2012; 18(2):291-5. DOI: 10.1038/nm.2613. View

11.

Du G, Wang E, Sica C, Chen H, De Jesus S, Lewis M . Dynamics of Nigral Iron Accumulation in Parkinson's Disease: From Diagnosis to Late Stage. Mov Disord. 2022; 37(8):1654-1662. PMC: 9810258. DOI: 10.1002/mds.29062. View

12.

Guo C, Wang P, Zhong M, Wang T, Huang X, Li J . Deferoxamine inhibits iron induced hippocampal tau phosphorylation in the Alzheimer transgenic mouse brain. Neurochem Int. 2012; 62(2):165-72. DOI: 10.1016/j.neuint.2012.12.005. View

13.

Yu Q, Reale M, Kamal M, Holloway H, Luo W, Sambamurti K . Synthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, α-Synuclein synthesis, interleukin-1β release, and.... Antiinflamm Antiallergy Agents Med Chem. 2013; 12(2):117-28. PMC: 5214460. DOI: 10.2174/1871523011312020003. View

14.

Nelson P, Alafuzoff I, Bigio E, Bouras C, Braak H, Cairns N . Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012; 71(5):362-81. PMC: 3560290. DOI: 10.1097/NEN.0b013e31825018f7. View

15.

Dickson D . Dementia with Lewy bodies: neuropathology. J Geriatr Psychiatry Neurol. 2002; 15(4):210-6. DOI: 10.1177/089198870201500406. View

16.

Takahashi M, Dore S, Ferris C, Tomita T, Sawa A, Wolosker H . Amyloid precursor proteins inhibit heme oxygenase activity and augment neurotoxicity in Alzheimer's disease. Neuron. 2001; 28(2):461-73. DOI: 10.1016/s0896-6273(00)00125-2. View

17.

Kovacs G . Molecular Pathological Classification of Neurodegenerative Diseases: Turning towards Precision Medicine. Int J Mol Sci. 2016; 17(2). PMC: 4783923. DOI: 10.3390/ijms17020189. View

18.

Singleton A, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J . alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003; 302(5646):841. DOI: 10.1126/science.1090278. View

19.

Luo Y, Tian G, Fang X, Bai S, Yuan G, Pan Y . Ferroptosis and Its Potential Role in Glioma: From Molecular Mechanisms to Therapeutic Opportunities. Antioxidants (Basel). 2022; 11(11). PMC: 9686959. DOI: 10.3390/antiox11112123. View

20.

Damulina A, Pirpamer L, Soellradl M, Sackl M, Tinauer C, Hofer E . Cross-sectional and Longitudinal Assessment of Brain Iron Level in Alzheimer Disease Using 3-T MRI. Radiology. 2020; 296(3):619-626. DOI: 10.1148/radiol.2020192541. View